Logo image of APVO

APTEVO THERAPEUTICS INC (APVO) Stock Price, Quote, News and Overview

NASDAQ:APVO - Nasdaq - US03835L4059 - Common Stock - Currency: USD

0.74  +0.05 (+6.72%)

After market: 0.7001 -0.04 (-5.39%)

APVO Quote, Performance and Key Statistics

APTEVO THERAPEUTICS INC

NASDAQ:APVO (4/23/2025, 8:00:00 PM)

After market: 0.7001 -0.04 (-5.39%)

0.74

+0.05 (+6.72%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High51.06
52 Week Low0.6
Market Cap2.38M
Shares3.22M
Float3.02M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-06 2025-05-06
IPO07-20 2016-07-20


APVO short term performance overview.The bars show the price performance of APVO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60 -80

APVO long term performance overview.The bars show the price performance of APVO in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of APVO is 0.74 USD. In the past month the price decreased by -58.66%. In the past year, price decreased by -97.17%.

APTEVO THERAPEUTICS INC / APVO Daily stock chart

APVO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.5 313.20B
AMGN AMGEN INC 14.02 149.41B
GILD GILEAD SCIENCES INC 23.08 132.62B
VRTX VERTEX PHARMACEUTICALS INC 1698 126.59B
REGN REGENERON PHARMACEUTICALS 12.88 64.26B
ARGX ARGENX SE - ADR 319.7 36.31B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 31.48B
BNTX BIONTECH SE-ADR N/A 27.60B
ONC BEIGENE LTD-ADR N/A 26.85B
SMMT SUMMIT THERAPEUTICS INC N/A 24.51B
NTRA NATERA INC N/A 20.08B
BIIB BIOGEN INC 7.17 17.30B

About APVO

Company Profile

APVO logo image Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. The company is headquartered in Seattle, Washington and currently employs 37 full-time employees. The company went IPO on 2016-07-20. The firm has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The firm has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.

Company Info

APTEVO THERAPEUTICS INC

2401 4th Ave Ste 1050

Seattle WASHINGTON 98121 US

CEO: Marvin L. White

Employees: 40

Company Website: https://aptevotherapeutics.com/

Investor Relations: http://aptevotherapeutics.gcs-web.com/financial-reports/sec-filings

Phone: 12068380500

APTEVO THERAPEUTICS INC / APVO FAQ

What is the stock price of APTEVO THERAPEUTICS INC today?

The current stock price of APVO is 0.74 USD. The price increased by 6.72% in the last trading session.


What is the ticker symbol for APTEVO THERAPEUTICS INC stock?

The exchange symbol of APTEVO THERAPEUTICS INC is APVO and it is listed on the Nasdaq exchange.


On which exchange is APVO stock listed?

APVO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for APTEVO THERAPEUTICS INC stock?

7 analysts have analysed APVO and the average price target is 21.42 USD. This implies a price increase of 2794.59% is expected in the next year compared to the current price of 0.74. Check the APTEVO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is APTEVO THERAPEUTICS INC worth?

APTEVO THERAPEUTICS INC (APVO) has a market capitalization of 2.38M USD. This makes APVO a Nano Cap stock.


How many employees does APTEVO THERAPEUTICS INC have?

APTEVO THERAPEUTICS INC (APVO) currently has 40 employees.


What are the support and resistance levels for APTEVO THERAPEUTICS INC (APVO) stock?

APTEVO THERAPEUTICS INC (APVO) has a resistance level at 1. Check the full technical report for a detailed analysis of APVO support and resistance levels.


Should I buy APTEVO THERAPEUTICS INC (APVO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does APTEVO THERAPEUTICS INC (APVO) stock pay dividends?

APVO does not pay a dividend.


When does APTEVO THERAPEUTICS INC (APVO) report earnings?

APTEVO THERAPEUTICS INC (APVO) will report earnings on 2025-05-06.


What is the Price/Earnings (PE) ratio of APTEVO THERAPEUTICS INC (APVO)?

APTEVO THERAPEUTICS INC (APVO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-530.07).


What is the Short Interest ratio of APTEVO THERAPEUTICS INC (APVO) stock?

The outstanding short interest for APTEVO THERAPEUTICS INC (APVO) is 4.11% of its float. Check the ownership tab for more information on the APVO short interest.


APVO Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

APVO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to APVO. APVO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

APVO Financial Highlights

Over the last trailing twelve months APVO reported a non-GAAP Earnings per Share(EPS) of -530.07. The EPS decreased by -713.99% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -167.24%
ROE -559.13%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-1237.18%
Sales Q2Q%N/A
EPS 1Y (TTM)-713.99%
Revenue 1Y (TTM)N/A

APVO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to APVO. The Buy consensus is the average rating of analysts ratings from 7 analysts.


Ownership
Inst Owners3.33%
Ins Owners0.01%
Short Float %4.11%
Short Ratio1.19
Analysts
Analysts82.86
Price Target21.42 (2794.59%)
EPS Next Y96.95%
Revenue Next YearN/A